Drug Efficacy: Hearings Before a Subcommittee of the Committee on Government Operations, House of Representatives, Ninety-first Congress, First Session, 1. daļaU.S. Government Printing Office, 1970 - 415 lappuses |
No grāmatas satura
1.5. rezultāts no 46.
. lappuse
... of Representatives, Ninety-first Congress, First Session United States. Congress. House. Committee on Government Operations. Intergovernmental Relations Subcommittee. 7 70 37-3 HEARINGS BEFORE A 4 - APR - 9 Copy SUBCOMMITTEE.
... of Representatives, Ninety-first Congress, First Session United States. Congress. House. Committee on Government Operations. Intergovernmental Relations Subcommittee. 7 70 37-3 HEARINGS BEFORE A 4 - APR - 9 Copy SUBCOMMITTEE.
. lappuse
... Copy SUBCOMMITTEE OF THE COMMITTEE ON 1970 GOVERNMENT OPERATIONS . T HOUSE OF REPRESENTATIVES NINETY - FIRST CONGRESS FIRST SESSION APRIL 17 , 18 , AND 22 , 1969 Printed for the use of the Committee on Government Operations 72-606578 37 ...
... Copy SUBCOMMITTEE OF THE COMMITTEE ON 1970 GOVERNMENT OPERATIONS . T HOUSE OF REPRESENTATIVES NINETY - FIRST CONGRESS FIRST SESSION APRIL 17 , 18 , AND 22 , 1969 Printed for the use of the Committee on Government Operations 72-606578 37 ...
4. lappuse
... copies of telegrams that issued today to Parke , Davis & Co. and Rachelle Laboratories show the actions that we are tak- ing with regard to chloramphenicol succinate injections , about which you and Mrs. Dwyer inquired on April 4 , 1969 ...
... copies of telegrams that issued today to Parke , Davis & Co. and Rachelle Laboratories show the actions that we are tak- ing with regard to chloramphenicol succinate injections , about which you and Mrs. Dwyer inquired on April 4 , 1969 ...
5. lappuse
... copies of your statement well in advance of the hearings and copies are available for the press . would you care to give us a brief summary of the major points in your statement and let us incorporate 5.
... copies of your statement well in advance of the hearings and copies are available for the press . would you care to give us a brief summary of the major points in your statement and let us incorporate 5.
7. lappuse
... copy of the labeling as revised in 1966.1 The " box warning " in the labeling was strongly worded . It told the physicians quite bluntly the dangers of the drug , yet it had not accomplished its intended purpose . Despite the risks ...
... copy of the labeling as revised in 1966.1 The " box warning " in the labeling was strongly worded . It told the physicians quite bluntly the dangers of the drug , yet it had not accomplished its intended purpose . Despite the risks ...
Citi izdevumi - Skatīt visu
Bieži izmantoti vārdi un frāzes
Academy action amphenicol antibiotic aplastic anemia approved April blood level data blood level studies Brandenburg BROWN Bureau of Medicine certification Chairman chloram chloramphenicol capsules chloramphenicol products chloramphenicol sodium succinate chloramphenicol succinate Chloromycetin sodium succinate Chloromycetin succinate clinical data CONGRESS THE LIBRARY Davis & Co Davis product Dear Doctor decision Director dissolution rates Documentation dosage forms dose Drug Administration effective efficacy evaluation evidence files firm Food and Drug FOUNTAIN GOLDBERG GOODRICH gram GRAY HERBERT L Hodges hospital indicated injection insert intramuscular route intravenous JENNINGS July July 26 KIRK letter LIBRARY OF CONGRESS LOCKHART memorandum meningitis MINCHEW Office old labeling oral product parenteral parenteral form Parke patients pediatric percent phenicol physicians Pirtle problem question Rachelle Laboratories Rachelle product Rachelle's recall recommended record relabeling routes of administration September 1968 Staphylococcal statement subcommittee subcutaneous submitted therapeutic therapy tion typhoid fever vials warehouses
Populāri fragmenti
66. lappuse - ... should be decreased as soon as possible. Adults with impairment of hepatic or renal function or both may have reduced ability to metabolize and excrete the drug. In instances of impaired metabolic processes, dosages should be adjusted accordingly. (See discussion under Newborn Infants.) Precise control of concentration of the drug in the blood should be carefully followed in patients with impaired metabolic processes by the available microtechniques (information available on request).
63. lappuse - In addition, there have been reports of aplastic anemia attributed to chloramphenicol which later terminated in leukemia. Blood dyscrasias have occurred after both short-term and prolonged therapy with this drug. Chloramphenicol must not be used when less potentially dangerous agents will be effective, as described in the Indications section.
64. lappuse - Warning Box and this Indications section, chloramphenicol must be used only in those serious Infections for which less potentially dangerous drugs are ineffective or contraindlcated.
113. lappuse - Chloramphenicol should not be used when other less potentially dangerous agents will be effective, or in the treatment of trivial infections such as colds, influenza, or viral infections of the throat, or as a prophylactic agent.
57. lappuse - It must not be used in the treatment of trivial infections or where it is not indicated, as in colds, influenza, infections of the throat; or as a prophylactic agent to prevent bacterial infections. Precautions: It is essential that adequate blood studies be made during treatment with the drug. While blood studies may detect early peripheral blood changes, such as leukopenia, reticulocytopenia, or granulocytopenia. before they become irreversible, such studies cannot be relied on to detect bone marrow...
65. lappuse - An exact determination of the risk of serious and fatal blood dyscrasias is not possible because of lack of accurate information regarding (1) the size of the population at risk, (2) the total number of drug-associated dyscrasias, and (3) the total number of nondrugassociated dyscrasias. In a report to the California State Assembly by the California Medical Association and the State Department of Public Health...
65. lappuse - ... after the administration of chloramphenicol. An irreversible type of marrow depression leading to aplastic anemia with a high rate of mortality is characterized by the appearance weeks or months after therapy of bone marrow aplasia or hypoplasia. Peripherally...
63. lappuse - Sensitivity testing is essential to determine its indicated use. but may be performed concurrently with therapy initiated on clinical impression that one of the indicated conditions exists (see Indications section).
65. lappuse - ... Treatment should not be continued longer than required to produce a cure with little or no risk of relapse of the disease. 3. Concurrent therapy with other drugs that may cause bone marrow depression should be avoided. 4. Excessive blood levels may result from administration of the recommended dose to patients with impaired liver or kidney function, including that due to immature metabolic processes in the infant.
62. lappuse - Gray Syndrome" Toxic reactions including fatalities have occurred in the premature and newborn; the signs and symptoms associated with these reactions have been referred to as the gray syndrome. One case of gray syndrome has been reported in an infant born to a mother having received chloramphenicol during labor.